For research use only. Not for therapeutic Use.
IMR-1(CAT: I003097) is a member of a novel class of Notch inhibitors. This compound is designed to specifically target the transcriptional activation process of the Notch signaling pathway. Notch signaling plays a critical role in various cellular processes, including development, differentiation, and proliferation. By inhibiting this pathway, IMR-1 has the potential to influence cellular responses and contribute to the regulation of various biological activities.
| Catalog Number | I003097 |
| CAS Number | 310456-65-6 |
| Synonyms | (E)-ethyl 2-(2-methoxy-4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)phenoxy)acetate |
| Molecular Formula | C₁₅H₁₅NOS₂ |
| Purity | ≥95% |
| Target | Notch |
| Solubility | DMSO: ≥ 31 mg/mL |
| Storage | Store at -20°C |
| InChI | InChI=1S/C15H15NO5S2/c1-3-20-13(17)8-21-10-5-4-9(6-11(10)19-2)7-12-14(18)16-15(22)23-12/h4-7H,3,8H2,1-2H3,(H,16,18,22)/b12-7+ |
| InChIKey | QHPJWPQRZMBKTG-KPKJPENVSA-N |
| SMILES | O=C(OCC)COC1=CC=C(/C=C(SC(N2)=S)C2=O)C=C1OC |
| Reference | </br>1:The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis. Astudillo L, Da Silva TG, Wang Z, Han X, Jin K, VanWye J, Zhu X, Weaver K, Oashi T, Lopes PE, Orton D, Neitzel LR, Lee E, Landgraf R, Robbins DJ, MacKerell AD Jr, Capobianco AJ.Cancer Res. 2016 Jun 15;76(12):3593-603. doi: 10.1158/0008-5472.CAN-16-0061. Epub 2016 Apr 13. PMID: 27197169 </br>2:[Effeco of sarcolysine on the growth and morphological characteristics of IMR-1 sarcoma]. Svinogeeva TP, Kharlampovich SI.Vopr Onkol. 1974;20(4):98-9. Russian. No abstract available. PMID: 4439824 </br>3:[Combined drug and radiation therapy of IMR-1 sarcoma with regard to its mitotic activity]. Kharlampovich SI.Vopr Onkol. 1970;16(1):75-82. Russian. No abstract available. PMID: 5434579 </br>4:[Transplanted sarcoma (IMR-1) in /August/ strain rats]. Kharlampovich SI, Podsosov SP.Vopr Onkol. 1966 Apr;12(4):83-6. Russian. No abstract available. PMID: 6001005 |
